Uso terapêutico de corticosteroides inalados em prematuros com broncodisplasia pulmonar: Uma revisão de literatura dos últimos 25 anos
DOI:
https://doi.org/10.33448/rsd-v14i9.49489Palavras-chave:
Displasia broncopulmonar, Recém-nascido prematuro, Terapêutica, Corticosteroides inalatórios.Resumo
Introdução: A displasia broncopulmonar (DBP) é definida como condição caracterizada pela dependência de oxigenioterapia de alta concentração e/ou ventilação mecânica até a 36º semana pós-concepção, associada a alterações radiológicas. O objetivo desta revisão é analisar de forma crítica e sistematizada a eficácia e a segurança dos corticosteroides inalatórios no manejo da broncodisplasia pulmonar em prematuros, possibilitando uma conclusão fundamentada nas melhores evidências disponíveis até o momento. Foi realizada uma pesquisa tipo revisão de literatura tipo narrativa, de documentos encontrados nos sites oficiais do PubMed®, Scielo®, Cochrane Library®, Science Direct® e Springer Link®, disponíveis entre os anos de 2000 e 2025, de acesso ao público. Resultados: As buscas resultaram em 1492 artigos no total, e após aplicação dos critérios de inclusão e exclusão, foram selecionados 25 artigos. Conclusão: A revisão da literatura evidencia que, apesar da maioria dos estudos demonstrarem resultados positivos no uso de corticoides inalatórios, como Beclometasona e Budesonida, ainda não existe uma padronização das doses ou tempo de uso. Apesar dos avanços, ainda existem divergências significativas quanto a sua eficácia, segurança e efeitos a longo prazo. Essa heterogeneidade reflete a complexidade do manejo da DBP, por isso é essencial analisar de forma crítica e sistematizada a eficácia e a segurança dos corticosteroides inalatórios, possibilitando uma conclusão fundamentada nas melhores evidências disponíveis até o momento.
Referências
Abman, S. H. (2006). Bronchopulmonary dysplasia: “A vascular hypothesis.” American Journal of Respiratory and Critical Care Medicine, 164(12), 1755–1756.
Ambalavanan, N., Van Meurs, K. P., Perritt, R., Carlo, W. A., Ehrenkranz, R. A., Stevenson, D. K., et al. (2008). Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure. Journal of Perinatology, 28(6), 420–426. https://doi.org/10.1038/jp.2008.18
Bancalari, E., & Claure, N. (2006). Diagnosis and treatment of bronchopulmonary dysplasia. Seminars in Neonatology, 11(5), 351–361. https://doi.org/10.1016/j.siny.2006.06.007
Bancalari, E., & Jain, D. (2019). Bronchopulmonary dysplasia: 50 years after the original description. Neonatology, 115(4), 384–391.
Bancalari, E., Abdenour, G. E., Feller, R., & Gannon, J. (1979). Bronchopulmonary dysplasia: Clinical presentation. Journal of Pediatrics, 95(5), 819–823.
Bassler, D., Plavka, R., Shinwell, E. S., et al. (2015). Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. New England Journal of Medicine, 373(16), 1497–1506. https://doi.org/10.1056/NEJMoa1505719
Bassler, D., Plavka, R., Shinwell, E. S., Hallman, M., Jarreau, P. H., Carnielli, V., ... & Halliday, H. L. (2015). Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. New England Journal of Medicine, 373(16), 1497–1506. https://doi.org/10.1056/NEJMoa1501917
Bassler, D., Shinwell, E. S., Hallman, M., Jarreau, P. H., Plavka, R., Carnielli, V., ... & Poets, C. F. (2018). Long-term effects of inhaled budesonide for bronchopulmonary dysplasia. New England Journal of Medicine, 378(2), 148–157. https://doi.org/10.1056/NEJMoa1708831
Baud, O., et al. (2022). Budesonide for the prevention of bronchopulmonary dysplasia. New England Journal of Medicine, 386(7), 630–639.
Baud, O., Mauri, M., Guimaraes, H., et al. (2022). Efficacy and safety of budesonide with surfactant for prevention of bronchopulmonary dysplasia: A randomized clinical trial. JAMA Pediatrics, 176(6), 527–535. https://doi.org/10.1001/jamapediatrics.2021.6629
Bose, C., Dammann, C. E. L., & Laughon, M. M. (2008). BPD and inflammatory biomarkers in the premature neonate. Archives of Disease in Childhood - Fetal and Neonatal Edition, 93(F5), F455–F461.
Bose, C., Van Marter, L. J., Laughon, M., O’Shea, T. M., Allred, E. N., Karna, P., et al. (2009). Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. Pediatrics, 124(3), e450–e458. https://doi.org/10.1542/peds.2008-3249
Costa, P. F. B. M. (2013). Displasia broncopulmonar. Pulmão RJ, 22(3), 37–42.
Crossetti, M. G. O. (2012). Revisão integrativa de pesquisa na enfermagem: O rigor científico que lhe é exigido. Revista Gaúcha de Enfermagem, 33(2), 8–13. http://hdl.handle.net/10183/94920
Crowley, P. (2000). Prophylactic corticosteroids for preterm birth. Cochrane Database of Systematic Reviews, (2), CD000065. https://doi.org/10.1002/14651858.CD000065
Cruz, C. H., et al. (2009). Incidência e fatores de risco para displasia broncopulmonar em recém-nascidos de muito baixo peso em hospitais universitários públicos de Maceió. Revista Brasileira de Saúde Materno Infantil, 9(2), 139–145.
Currie, C. J., Hodgson, J., & McGuire, W. (2019). Inhaled corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews, 7(7), CD003311. https://doi.org/10.1002/14651858.CD003311.pub4
Doyle, L. W., Cheong, J. L. Y., Ehrenkranz, R. A., & Halliday, H. L. (2017). Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants. Cochrane Database of Systematic Reviews, 2017(10), CD002057. https://doi.org/10.1002/14651858.CD002057.pub3
Doyle, L. W., Faber, B., Callanan, C., & Morley, C. J. (2006). A randomized controlled trial of inhaled budesonide in the treatment of established bronchopulmonary dysplasia. Pediatrics, 118(2), 579–584. https://doi.org/10.1542/peds.2005-2192
Doyle, L. W., Halliday, H. L., Ehrenkranz, R. A., & Davis, P. G. (2017). Late (>7 days) systemic postnatal corticosteroids for prevention of chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews, 10(10), CD001145.
El-Atawi, K., Abdul Wahab, M. G., Alallah, J., et al. (2024). Beyond bronchopulmonary dysplasia: A comprehensive review of chronic lung diseases in neonates. Cureus, 16(7), e64804. https://doi.org/10.7759/cureus.64804
El-Saie, A., Varghese, N. P., Webb, M. K., et al. (2023). Bronchopulmonary dysplasia–associated pulmonary hypertension: An updated review. Seminars in Perinatology, 47(6), 151817. https://doi.org/10.1016/j.semperi.2023.151817
Fernandes, A. D. P. (2012). Displasia broncopulmonar (Trabalho de conclusão de curso, Faculdade de Medicina da Universidade de Coimbra).
Finer, N. N., & Barrington, K. J. (2006). Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database of Systematic Reviews, (3), CD000399. https://doi.org/10.1002/14651858.CD000399.pub2
Fontijn, J., Engel, C., Kreutzer, K. B., Poets, C., & Bassler, D. (2025). Influence of antenatal steroids on the effect of early inhaled postnatal corticosteroids: A post-hoc analysis of the NEuroSIS trial. BMC Pediatrics, 25(1), 172. https://doi.org/10.1186/s12887-025-05512-z
Guinsburg, R., et al. (2011). Incidência de displasia broncopulmonar em recém-nascidos prematuros no Brasil: dados da rede NEOCOSUR. Jornal de Pediatria, 87(4), 324–329. https://doi.org/10.1590/S0021-75572011000400006
Gupta, G. K., Cole, C. H., Abbasi, S., Demissie, S., Njinimbam, C., Nielsen, H. C., Colton, T., & Frantz, I. D. III. (2000). Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. Pediatric Pulmonology, 30(4), 275–281. https://doi.org/10.1002/1099-0496(200010)30:4<275:AID-PPUL1>3.0.CO;2-G
Halliday, H. L., Ehrenkranz, R. A., & Doyle, L. W. (2003). Delayed (> 3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews, (3), CD001145. https://doi.org/10.1002/14651858.CD001145
Halliday, H. L., Ehrenkranz, R. A., & Doyle, L. W. (2003). Early postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews, (1), CD001146. https://doi.org/10.1002/14651858.CD001146
Halliday, H. L., Patterson, C. C., & Halahakoon, C. W. (2001). A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: Comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics, 107(2), 232–240. https://doi.org/10.1542/peds.107.2.232
Heo, J. H., Kim, J. H., Lee, J. H., et al. (2024). Intratracheal budesonide mixed with surfactant for prevention of bronchopulmonary dysplasia in preterm infants: A randomized controlled trial. Pediatric Pulmonology, 59(3), 450–457. https://doi.org/10.1002/ppul.25890
Higgins, R. D., Jobe, A. H., Koso-Thomas, M., et al. (2018). Bronchopulmonary dysplasia: Executive summary of a workshop. Journal of Pediatrics, 197, 300–308.e1. https://doi.org/10.1016/j.jpeds.2018.01.043
Jobe, A. H., & Bancalari, E. (2001). Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine, 163(7), 1723–1729. https://doi.org/10.1164/ajrccm.163.7.2011060
Kim, Y. H., Choi, C. W., Kim, E. K., Kim, H. S., & Choi, J. H. (2020). Comparison of inhaled corticosteroids and systemic steroids for management of bronchopulmonary dysplasia in very low birth weight infants. Pediatric Pulmonology, 55(1), 55–61. https://doi.org/10.1002/ppul.24542
Kotecha, S., Wilson, L., & Wangoo, A. (1996). Increase in interleukin (IL)-1β and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatric Research, 40(2), 250–256.
Lavoie, P. M., Pham, C., & Jang, K. L. (2008). Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the National Institutes of Health. Pediatrics, 122(3), 479–485. https://doi.org/10.1542/peds.2007-2313
Leon, C., Martin, A., Young, L. R., Aoyama, B. C., Rice, J. L., Kelchtermans, J., Collaco, J. M., & McGrath-Morrow, S. A. (2024). Outpatient inhaled corticosteroid use in bronchopulmonary dysplasia. Pediatric Pulmonology.https://doi.org/10.1002/ppul.27134
Leone, T. A., & Finer, N. N. (2010). Mechanical ventilation: Early strategies to decrease BPD. In S. H. Abman (Ed.), Bronchopulmonary dysplasia (pp. 314–327). New York: Informa Healthcare.
Lin, Y. J., Markham, R., Ramirez, R., & Chao, P. W. (2017). Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: A meta-analysis with trial sequential analysis. BMC Pulmonary Medicine, 17, 135. https://doi.org/10.1186/s12890-017-0550-z
Menezes, M. S. D., Dias, V. F., Araújo, D. D., et al. (2024). Incidência e fatores associados à displasia broncopulmonar em egressos de Unidades de Terapia Intensiva Neonatal no norte de Minas Gerais. Revista Brasileira de Saúde Materno Infantil. https://doi.org/10.1590/1806-9304202400000277
Mokres, L. M., Parai, K., & Hilgenforff, A. (2010). Prolonged mechanical ventilation with air induces apoptosis and causes failure of alveolar septation and angiogenesis in lungs of newborn mice. American Journal of Physiology, 298(1), L23–L35.
Monte, L. F. V., Silva Filho, L. V. F. da, Miyoshi, M. H., & Rozov, T. (2005). Displasia broncopulmonar. Jornal de Pediatria, 81(2), 99–110. https://doi.org/10.1590/S0021-75572005000300004
Moreira, A., Noronha, M., Joy, J., et al. (2024). Rates of bronchopulmonary dysplasia in very low birth weight neonates: A systematic review and meta-analysis. Respiratory Research, 25, 219. https://doi.org/10.1186/s12931-024-02850-x
Moreira, C. A. R., & Guerra, P. (2023). Displasia broncopulmonar: Revisão narrativa da literatura. Journal of Medical Residency Review, 2(1), e037. https://doi.org/10.37497/JMRReview.v2i1.37
Nair, V., Goyal, N. K., Kumar, P., Sankar, M. J., & Deorari, A. K. (2022). Efficacy and safety of early inhaled corticosteroids in very low birth weight infants: A randomized controlled trial. Indian Pediatrics, 59(6), 475–480. https://doi.org/10.1007/s13312-022-2556-2
Nakamura, T., Yonemoto, N., Nakayama, M., Hirano, S., Aotani, H., Kusuda, S., et al. (2016). Early inhaled steroid use in extremely low birthweight infants: A randomised controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition. Advance online publication. https://doi.org/10.1136/archdischild-2015-309943
Northway, W. H., Rosan, R. C., & Porter, D. Y. (1967). Pulmonary disease following respiratory therapy of hyaline-membrane disease: Bronchopulmonary dysplasia. New England Journal of Medicine, 276(7), 357–368.
Papazian, L., Camus, C., & Koshkarian, J. (1990). Effects of glucocorticoids on airway inflammation and remodeling in bronchopulmonary dysplasia. American Journal of Respiratory Cell and Molecular Biology, 3(4), 293–301.
Park, J. H., Kim, J. H., Kim, H. S., Choi, C. W., & Kim, E. K. (2023). Long-term pulmonary outcomes following inhaled corticosteroid treatment in preterm infants with bronchopulmonary dysplasia. European Journal of Pediatrics, 182(2), 521–528. https://doi.org/10.1007/s00431-023-04711-0
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica [eBook gratuito]. Editora da UFSM. https://repositorio.ufsm.br/handle/1/1582
Raghuram, K., Dunn, M., Jangaard, K., Reilly, M., Asztalos, E., Kelly, E., Vincer, M., & Shah, V. (2018). Inhaled corticosteroids in ventilated preterm neonates: A non-randomized dose-ranging study. BMC Pediatrics, 18(1), 153. https://doi.org/10.1186/s12887-018-1134-7
Rojas, M., Gonzalez, A., & Bancalari, E. (1995). Bronchopulmonary dysplasia: Clinical characteristics and pathophysiology. Clinics in Perinatology, 22(3), 597–610.
Sampalis, J., Karampelas, A., & Kumpfer, A. (2019). Surfactant therapy in preterm infants: Past, present, and future. Pediatric Pulmonology, 54(9), 1435–1443.
Shah, S. S., Ohlsson, A., Halliday, H. L., & Shah, V. S. (2003). Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews, 2003(1), CD002058. https://doi.org/10.1002/14651858.CD002058
Shah, S. S., Ohlsson, A., Halliday, H. L., & Shah, V. S. (2017). Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews, 2017(10), CD002058. https://doi.org/10.1002/14651858.CD002058.pub3
Shennan, A. T., Dunn, M. S., Ohlsson, A., Lennox, K., & Hoskins, E. M. (1988). Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period. Pediatrics, 82(4), 527–532.
Shinwell, E. S., Portnov, I., Meerpohl, J. J., Karen, T., & Bassler, D. (2016). Inhaled corticosteroids for bronchopulmonary dysplasia: A meta-analysis. Pediatrics, 138(6), e20162511. https://doi.org/10.1542/peds.2016-2511
Shitsuka, R., et al. (2014). Matemática fundamental para a tecnologia (2ª ed.). Editora Érica.
Siffel, C., Kistler, K. D., Lewis, J. F. M., & Sarda, S. P. (2021). Global incidence of bronchopulmonary dysplasia among extremely preterm infants: A systematic literature review. Journal of Maternal-Fetal & Neonatal Medicine, 34(11), 1721–1731. https://doi.org/10.1080/14767058.2019.1646240
Vanhaverbeke, K., Van Eyck, A., Van Hoorenbeeck, K., De Winter, B., Snoeckx, A., Mulder, T., et al. (2020). Lung imaging in bronchopulmonary dysplasia: A systematic review. Respiratory Medicine, 171, 106101. https://doi.org/10.1016/j.rmed.2020.106101
Vieira, S. (2021). Introdução à bioestatística. Editora GEN/Guanabara Koogan
Walsh, M. C., Szefler, S., Davis, J., et al. (2006). Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics, 117(Supplement 3), S52.
Wang, X., Lu, Y. K., Wu, Y. Y., et al. (2023). Comparison of two novel diagnostic criteria for bronchopulmonary dysplasia in predicting adverse outcomes of preterm infants: A retrospective cohort study. BMC Pulmonary Medicine, 23(1), 308. https://doi.org/10.1186/s12890-023-02590-6
Younge, N., Goldstein, R. F., Bann, C. M., Hintz, S. R., Patel, R. M., Smith, P. B., et al. (2017). Survival and neurodevelopmental outcomes among periviable infants. The New England Journal of Medicine, 376(7), 617–628. https://doi.org/10.1056/NEJMoa1605566
Zhang, M., Zhang, W., & Liao, H. (2024). Efficacy and safety of different inhaled corticosteroids for bronchopulmonary dysplasia prevention in preterm infants: A systematic review and meta-analysis. Respiratory Medicine Research, 85, 101096. https://doi.org/10.1016/j.resmer.2024.101096
Zhang, Y., Liu, X., Wang, Y., et al. (2025). Inhaled corticosteroids for prevention and treatment of bronchopulmonary dysplasia: A meta-analysis of randomized controlled trials. Respiratory Research, 26(1), 45. https://doi.org/10.1186/s12931-025-02045-7
Zhang, Z.-Q., Zhong, Y., Huang, X.-M., & Du, L.-Z. (2017). Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: A meta-analysis with trial sequential analysis. BMC Pulmonary Medicine, 17, 207. https://doi.org/10.1186/s12890-017-0550-z
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2025 Maressa Prieto Souza de Oliveira, Keila Maria Lima Miguel Lorenzi
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
